Functional consequences of mTOR inhibition

被引:0
作者
Sudarsanam, Sucha [1 ]
Johnson, Dale E. [1 ]
机构
[1] Emiliem Inc, Emeryville, CA 94608 USA
关键词
Cancer; diabetes; lifespan extension; mTOR; ocular disease; rapamycin; sirolimus; MAMMALIAN TARGET; LIFE-SPAN; CALORIC RESTRICTION; RAPAMYCIN; PHOSPHORYLATION; CANCER; AKT; ACTIVATION; PATHWAY; RESISTANCE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
TOR (target of rapamycin) is a serine-threonine protein kinase that is conserved across a diverse range of species from fungi to mammals. The signaling pathway that is anchored by TOR is also conserved across species. In mammals, mTOR integrates growth factor, amino acid, nutrient and energy sensing signals, and thus plays a major role in cell growth and proliferation, protein synthesis and autophagy. As a result of the pivotal role of mTOR in signaling, the aberrant regulation of mTOR has been implicated in several disease processes, including cancer, diabetes, ocular diseases and neurodegenerative disorders, as well as in lifespan extension. More recently, rapamycin (sirolimus) analogs that antagonize the mTOR signaling pathway have been approved for the treatment of several cancers. This review describes some recent advances in the understanding of mTOR signaling, with an emphasis on the functional consequences of mTOR inhibition and therapeutic intervention strategies.
引用
收藏
页码:31 / 40
页数:10
相关论文
共 74 条
[1]   NV-128, a Novel Isoflavone Derivative, Induces Caspase-independent Cell Death Through the Akt/Mammalian Target of Rapamycin Pathway [J].
Alvero, Ayesha B. ;
Montagna, Michele K. ;
Chen, Rui ;
Kim, Ki Hyung ;
Kyungjin, Kim ;
Visintin, Irene ;
Fu, Han-Hsuan ;
Brown, David ;
Mor, Gil .
CANCER, 2009, 115 (14) :3204-3216
[2]   A module of negative feedback regulators defines growth factor signaling [J].
Amit, Ido ;
Citri, Ami ;
Shay, Tal ;
Lu, Yiling ;
Katz, Menachem ;
Zhang, Fan ;
Tarcic, Gabi ;
Siwak, Doris ;
Lahad, John ;
Jacob-Hirsch, Jasmine ;
Amariglio, Ninette ;
Vaisman, Nora ;
Segal, Eran ;
Rechavi, Gideon ;
Alon, Uri ;
Mills, Gordon B. ;
Domany, Eytan ;
Yarden, Yosef .
NATURE GENETICS, 2007, 39 (04) :503-512
[3]   Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases [J].
Apsel, Beth ;
Blair, Jimmy A. ;
Gonzalez, Beatriz ;
Nazif, Tamim M. ;
Feldman, Morri E. ;
Aizenstein, Brian ;
Hoffman, Randy ;
Williams, Roger L. ;
Shokat, Kevan M. ;
Knight, Zachary A. .
NATURE CHEMICAL BIOLOGY, 2008, 4 (11) :691-699
[4]   Everolimus [J].
Atkins, Michael B. ;
Yasothan, Uma ;
Kirkpatrick, Peter .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (07) :535-536
[5]   Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor Complex [J].
Beevers, Christopher S. ;
Chen, Long ;
Liu, Lei ;
Luo, Yan ;
Webster, Nicholas J. G. ;
Huang, Shile .
CANCER RESEARCH, 2009, 69 (03) :1000-1008
[6]   The two TORCs and Akt [J].
Bhaskar, Prashanth T. ;
Hay, Nissim .
DEVELOPMENTAL CELL, 2007, 12 (04) :487-502
[7]   Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review [J].
Boehm, S. ;
Rothermundt, C. ;
Hess, D. ;
Joerger, M. .
GERONTOLOGY, 2010, 56 (03) :303-309
[8]   Phosphorylation of IRS proteins, insulin action, and insulin resistance [J].
Boura-Halfon, Sigalit ;
Zick, Yehiel .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2009, 296 (04) :E581-E591
[9]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[10]  
Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]